Platelet count may be linked with 30-day in-hospital mortality in patients with ESKD
Click Here to Manage Email Alerts
Key takeaways:
- Results showed an in-hospital mortality rate of 13.27% and median 188×10/L platelet count.
- Researchers also found a link between platelet count and 30-day in-hospital mortality.
There may be a nonlinear connection between platelet count and 30-day in-hospital mortality in patients with end-stage kidney disease in the ICU, according to researchers.
“Although previous studies have conclusively identified aging, diabetes, hypertension and glomerulonephritis as the leading causes of ESKD, these underlying conditions are prevalent and intertwined in ICU-hospitalized ESKD patients,” Pan Zhou and Yun Li, of the Shenzhen Second People’s Hospital in China, wrote with colleague Jian-hui Xiao, of the Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine. “Consequently, some studies have begun to focus on the relationship between laboratory biomarkers and the prognosis of patients with [chronic kidney disease] CKD.”
Researchers analyzed data from the eICU Collaborative Research Database, a multicenter resource of 200,859 patients admitted to ICUs in 208 U.S. hospitals from 2014 to 2015.
The retrospective cohort study included 3,700 patients with ESKD in an ICU. Researchers focused on platelet count and 30-day in-hospital mortality. Results showed a 30-day in-hospital mortality rate of 13.27% and a median platelet count of 188×10/L. Researchers also found a link between platelet count and 30-day in-hospital mortality after adjusting for covariates (OR=0.98, 95% CI, 0.97, 0.99). The findings were confirmed by subgroup analyses.
Researchers found a significant difference in mortality risk based on platelet count, which “explicitly suggests that when ESRD patients are admitted to the ICU, a platelet level closer to 222×10/L may predict a lower 30-day in-hospital mortality risk,” according to Zhou and colleagues.
“Given the unique physiological basis of critically ill patients, we hypothesize that baseline platelet count before treatment may be associated with the short-term prognosis of ESRD. High-quality multicenter data elucidating this association can provide perspectives for future research,” they wrote.
Collapse
Click Here to Manage Email Alerts